# US 2005/0020489 A1 · Use of hcg and lh in controlled ovarian hyperstimulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0020489 A1
- Document ID: US20050020489A1
- Status: Published application
- Kind: A1
- Application number: 10/489,412
- Filed: 2002-09-12
- Published: 2005-01-27
- Earliest claimed: 2001-09-12
- Assignees: Laboratoires Seronosa
- Inventors: Yves Menezo
- Web page: https://patentgrep.com/patent/US20050020489A1

## CPC

- A61K 38/24: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61P 5/24: of the sex hormones
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- Y10S 930/11: Gonadotropin; related peptides
- Y10S 930/13: Luteinizing hormone-releasing hormone; related peptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG or LH, or a bio-analogue thereof, is administered during the follicular phase.

## Claims

### Claim 1

A method for aiding implantation and/or decreasing miscarriage rates, comprising administering human chorionic gonadotropin (hCG), or an analogue thereof, in conjunction with controlled ovarian hyperstimulation (COH) in human patients using FSH, or an analogue thereof, starting before the 10th day after commencing FSH treatment.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the medicament is administered starting before the 9th day after commencing FSH treatment.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the medicament is administered at least 3 days after commencing FSH treatment.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the medicament is administered starting on or about the 7th or 8th day after commencing FSH treatment.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the medicament is administered at a dosage of 25-1000 IU hCG/day.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the medicament is administered at a dosage of 50-100 IU hCG/day.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the medicament is administered as a single bolus.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the single bolus is administered on or about the 7th or 8th day after commencing FSH treatment, and the bolus comprises 100-500 IU hCG.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the medicament is administered on a daily basis until ovulation is induced.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the COH is carried out in conjunction with in vitro fertilisation or in vivo fertilisation.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the patients suffer from low endogenous LH levels.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the patients have previously exhibited failure to become or remain pregnant using FSH alone.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the hCG is recombinant hCG.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the hCG is urinary hCG.

### Claim 15 (depends on 1)

The method according to claim 1, wherein an analogue of hCG is used and wherein said analogue is a single chain hCG.

### Claim 16

A method for encouraging implantation and/or decreasing miscarriage rates of an embryo in a human patient, comprising administering human chorionic gonadotropin (hCG) or an analogue thereof, or human luteinising hormone (hLH), or an analogue thereof, before ovulation or ovulation triggering.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the medicament is administered as a single bolus on or about the 7th or 8th day after menses.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the medicament is administered on a daily basis, starting on or about the 7th or 8th day after menses and continuing until ovulation occurs.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the hCG or analogue thereof is recombinant hCG, urinary hCG or a single chain hCG.

### Claim 20

A pharmaceutical composition for use in conjunction with COH, for aiding implantation and/or decreasing miscarriage rates, comprising 25-1000 IU hCG, or an analogue thereof, or 125-7000 IU LH or an analogue thereof, per dosage.

### Claim 21 (depends on 20)

The pharmaceutical composition according to claim 20, comprising 75-125 IU hCG, or an analogue thereof, per dosage.

### Claim 22 (depends on 20)

The pharmaceutical composition according to claim 20, wherein the hCG or analogue thereof is recombinant hCG, urinary hCG or a single chain hCG.

### Claim 23

A method for aiding implantation and/or decreasing miscarriage rates, comprising administering human luteinising hormone (hLH), or an analogue thereof, in conjunction with controlled ovarian hyperstimulation (COH) in human patients using FSH, or an analogue thereof, starting before the 10th day after commencing FSH treatment.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the medicament is administered at a dosage of 125-7000 IU hLH/day.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the medicament is administered between 3 and 8 days after commencement of FSH treatment.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the patents are at least 35 years of age.

### Claim 27 (depends on 23)

The method according claim 23, wherein the hLH is recombinant hLH.

### Claim 28 (depends on 23)

The method according to claim 23, wherein the hLH is urinary hLH.

### Claim 29 (depends on 23)

The method according to claim 23, wherein an analogue of hLH is used.

### Claim 30 (depends on 1)

The method according to claim 1, wherein an analogue of FSH is used and wherein said analogue is FSH-CTP, or wherein FSH is replaced with an aromatase inhibitor or clomiphene citrate.

### Claim 31

A kit for use in COH comprising 12 or more daily doses of FSH, or an analogue thereof, and 4 to 8 daily doses of hCG, or an analogue thereof.

### Claim 32

A kit for aiding implantation of an embryo and/or decreasing miscarriage rates, comprising 4 to 8 daily doses of hCG, at about 25-1000 IU hCG/day, or an analogue thereof.
